Such responses across cell types may also impact therapeutic strategies targeting CC (e.g., CDK4/6 inhibitors), for example in cancer, and understanding the interplay between CC and immune activation may represent a promising avenue for therapeutic investigation. This evidence concerns the gene CDK4 and cancer.